Novartis Pharma AG: Novartis continues to grow with further core margin expansion and achieves important innovation milestones

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating

Related Keywords

China ,New Zealand ,Switzerland ,Germany ,Australia ,Japan ,United States ,Canada ,France ,America ,French ,German ,Swiss ,Johnd Young ,Charlesl Sawyers ,Bridgette Heller ,Elizabeth Doherty ,Patrice Bula ,Nancyc Andrews ,Simon Moroney ,Gleevec Glivec ,Daniel Hochstrasser ,Promacta Revolade ,Afinitor Votubia ,Joerg Reinhardt ,Frans Van Houten ,Moody Investors Service ,Pfizer Executive Leadership Team ,Novartis Group ,Arvinas Inc ,Diovan Group ,Compensation Committee ,Society Integrated ,Swiss Exchange ,Novartis ,Imbria Pharmaceuticals ,Exforge Group ,Exchange Commission ,Boards Of Johnson Controls International ,Galvus Group ,Committee Of Novartis ,Vas Narasimhan ,Innovative Medicines ,Condensed Financial ,Emerging Growth Markets ,Western Europe ,Malaria Venture ,Investors Service ,Novartis Board ,Annual General Meeting ,General Meeting ,Executive Leadership Team ,Johnson Controls International ,Board Chair ,Ton Buechner ,Ana De Pro Gonzalo ,Executive Committee ,Condensed Financial Report ,Society Integrated Report ,Profi Marcel Torney ,Dharma ,Ontinues ,Row ,Urther ,More ,Margin ,Expansion ,Chieves ,Important ,Innovation ,Ilestones ,